Geraldine Harriman has over seventeen years experience in the biotechnology industry in which she successfully delivered multiple "first in class" compounds against novel targets into clinical development. Prior to joining Nimbus, Gerry served as Vice President of Chemistry and member of the management team at Galenea where she was responsible for Galenea’s small molecule portfolio and served as Development Team Leader of Galenea's Phase Ib/II CIAS program. Prior to joining Galenea, she was Senior Director of Chemistry and Head of Inflammation Small Molecule Discovery at Millennium Pharmaceuticals and was responsible for the High Throughput Chemistry and Computational Chemistry Departments. Prior to her role at Millennium, she was one of the founding medicinal chemists at LeukoSite. Gerry received her PhD from the University of Rhode Island, followed by postdoctoral research at the University of Kansas. She is an author of over thirty publications, an author of several book chapters and an inventor on over twenty small molecule patents.